Shenzhen Qianhai Kejing Biotechnology Co., Ltd.

An exploratory clinical study to evaluate the safety and efficacy of NK cells (combined with standard therapy) in the treatment of solid tumor patients

1.研究MBC19治疗复发性或难治性B细胞淋巴瘤的安全性和耐受性。 2.研究MBC19的药代动力学特征。 3.探索MBC19最大耐受剂量（MTD）及推荐II期剂量（RP2D）。 4.研究MBC19治疗复发性或难治性B细胞淋巴瘤的细胞因子水平。 5.研究MBC19的免疫原性。 6.初步探索MBC19的抗肿瘤疗效。

A pilot study to determine the safety and efficacy of chimeric antigen receptor T cell (autologous T cells transduced with a lentiviral vector expressing chimeric antigen receptor with or without anti-PDL1 antibody) personalized immunotherapy for patients with recurrent malignant gliomas based on the expression of tumor specific/associated antigens (EGFRVIII, IL13Rα2, Her-2, EphA2, CD133, GD2).